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Abstract
Background: Studies have shown that early ART initiation in TB/HIV co-infected patients lowers mortality. One way to
implement earlier ART commencement could be through integration of TB and HIV services, a more efficient model of care
than separate, vertical programs. We present a model of full TB/HIV integration and estimate its effect on time to initiation
of ART.
Methodology/Principal Findings: We retrospectively reviewed TB registers and clinical notes of 209 TB/HIV co-infected
adults with a CD4 count,250 cells/ml and registered for TB treatment at one primary care clinic in a South African township
between June 2008 and May 2009. Using Kaplan-Meier and Cox proportional hazard analysis, we compared time between
initiation of TB treatment and ART for the periods before and after full, ‘‘one-stop shop’’ integration of TB and HIV services
(in December 2009). Potential confounders were determined a priori through directed acyclic graphs. Robustness of
assumptions was investigated by sensitivity analyses. The analysis included 188 patients (100 pre- and 88 post-integration),
yielding 56 person-years of observation. Baseline characteristics of the two groups were similar. Median time to ART
initiation decreased from 147 days (95% confidence interval [CI] 85–188) before integration of services to 75 days (95% CI
52–119) post-integration. In adjusted analyses, patients attending the clinic post-integration were 1.60 times (95% CI 1.11–
2.29) more likely to have started ART relative to the pre-integration period. Sensitivity analyses supported these findings.
Conclusions/Significance: Full TB/HIV care integration is feasible and led to a 60% increased chance of co-infected patients
starting ART, while reducing time to ART initiation by an average of 72 days. Although these estimates should be confirmed
through larger studies, they suggest that scale-up of full TB/HIV service integration in high TB/HIV prevalence settings may
shorten time to ART initiation, which might reduce excess mortality and morbidity.
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Introduction
In sub-Saharan Africa, an estimated 22.5 million people were
living with HIV/AIDS [1] and about 2.8 million [2] were
diagnosed with TB in 2009. South Africa is especially hard-hit by
the closely entwined TB and HIV epidemics, with an estimated
adult HIV prevalence of 17.8% [1] and an annual TB incidence of
970/100,000 [2]. In 2009 about 490,000 new TB cases were
diagnosed, of whom 58% were co-infected with HIV [2]. The two
diseases form a vicious spiral: TB is the main cause of death
among people living with HIV and AIDS [1], and HIV - which
drives the TB epidemic - is one of the main reasons for South
Africa’s failure to achieve TB control [2,3]. In addition, an
epidemic of multi-drug resistant tuberculosis (MDR-TB) has
emerged from the intersection of these two diseases [4,5].
HIV changes the clinical presentation of TB from a slowly
progressing disease with reasonable prognosis to one with a high
mortality rate [6]. TB-related mortality in HIV co-infected
patients is particularly high during the first months of TB
treatment [7]. Intervening more effectively during this critical
period is therefore essential to saving lives.
Evidence from randomised clinical trials as well as observational
data shows that early initiation of ART (between 2 and 8 weeks
after the start of TB treatment) improves survival [8–15]. Based on
these findings, WHO [16] and South African [17] guidelines
therefore recommend ART initiation during this time period.
However, in practice ART initiation is sometimes delayed [18]
due to factors such as patient characteristics, overlapping drug
toxicities, fear of clinicians, and national health policy.
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Structural barriers at different levels within the health system
also impede coordination of HIV/AIDS and TB activities,
negatively impacting TB/HIV prevention and care [19–21]. For
instance, a study from South Africa showed that ART initiation in
TB clinics can be delayed as much as 116 days, mainly due to
prolonged referral times in moving between TB and ART services
[22]. Well-documented shortages in human resources for health
care [23–26] also contribute to delays, and to primary health care
services becoming overwhelmed by increasing numbers of people
presenting with both diseases.
Clearly, continued implementation of vertical HIV/AIDS and
TB programs that treat each disease separately is inadequate and
must be replaced by new models of care. Vertical programs
involve duplication of services, which leads to inefficient use of
already-limited resources. In contrast, an integrated public health
approach to disease control utilizes available resources more
efficiently [27]. Varying levels of TB/HIV service integration have
been discussed extensively [21,28–30] and integration has shown
to be feasible and sustainable in various settings in sub-Saharan
Africa with dual TB and HIV epidemics [31–36]. However,
models of integration are not clearly outlined, and different
definitions of integration exist. A recent systematic review [21] of
TB/HIV services in low and middle income countries described
five models of integration, ranging from simple referral, to
collaboration between HIV and TB services, and to complete
integration of services. This review also highlighted the lack of
formal evidence on the impact of TB/HIV service integration, and
of comparative studies of outcomes under different models.
Since 2004 Me´decins Sans Frontie`res (MSF), the Provincial
Government of the Western Cape and the City of Cape Town
have piloted several models of TB/HIV integration in Khayelitsha
[20]. We hypothesized that complete service integration would
lead to faster initiation of ART in TB/HIV co-infected patients.
Our primary objectives were 1) to compare the time from the start
of TB treatment to ART initiation in eligible TB/HIV co-infected
adults before and after complete integration of TB and HIV
services in a primary care clinic in a South African township; and
2) to describe a ‘‘one stop shop’’ model of fully integrated TB and
HIV services. The broader aim is to develop an evidence base that
informs public health policy on the impact of this model of care.
Methods
Study setting
The township of Khayelitsha in Cape Town has more than
500,000 inhabitants and among the highest HIV and TB infection
rates both nationally and globally [37]. Town 2 clinic is one of 10
primary care clinics providing TB treatment, and treated 612
patients in 2008, out of an annual caseload of approximately 6000
TB cases for Khayelitsha. Until November 2008, Town 2 clinic
provided vertical TB care, HIV testing, CD4 counts, cotrimox-
azole prophylaxis and family planning, but co-infected patients
eligible for ART were referred to other ART sites in the sub-
district [37]. As of December 2008, ART initiation, pre- and post-
ART follow-up were integrated into TB services. This resulted in a
‘‘one stop shop’’ TB/HIV model of care where both services are
delivered by the same health professional at a single entry point
(Figure 1). Services provided pre- and post-integration are
described in Table S1.
Description of full ‘one stop shop’ TB/HIV
integration. Service integration was implemented at three tiers
of the health facility level: (1) administrative and managerial: one
facility manager oversees the provision of all HIV and TB service
activities; (2) health care provision: the same doctor, nurse,
counsellor, pharmacist assistant and clerk attends to all patients,
regardless of whether they have TB and/or HIV; and (3)
monitoring and evaluation: a single health information system
records data for both diseases in one patient file.
Infection control precautions are enforced through an infection
control policy addressing administrative, environmental and
individual protections. A poster describing the infection control
policy in detail is displayed in every clinic (Poster S1). An
Infection Control Committee, which consists of the facility
manager, a health and safety representative, a cough officer, the
TB/HIV nurses and a representative from the community, is
responsible for enforcing the policy. Major administrative control
items include six monthly infection control risk assessments;
screening of health care workers; education sessions for health
workers, patients and the community; cough triage; rapid
diagnosis and initiation of TB treatment; contact tracing; display
of TB signage and literature; and enforcement of environmental
and personal controls. Environmental controls focus on maximis-
ing low maintenance natural ventilation and ensure appropriate
directional flow in consultation rooms. Small infrastructural
changes were implemented to ensure a minimum of 12 air
changes per hour in every room; these include the installation of
additional windows, wind-driven roof turbines, an outside sputum
booth, and dry-wall partitioning to modify patient-flow. Personal
respiratory protection consists of distribution of surgical masks to
all coughing patients and N95 respirators to health care workers.
In addition to facility-level infection control interventions, the
MSF project team did regular education on infection control
measures on local radio, and conducted a campaign entitled ‘Stop
TB. Open your window’, targeting mini-van taxis and areas of
congregation.
Training in HIV management and provision of ART was
provided to all TB staff, and the clinic received reference tools
(HIV/TB treatment and counselling guidelines). For a six month
period, one additional nurse-mentor, one counsellor-mentor and
one data clerk-mentor were added to the existing staff (3 nurses,
one mobile doctor, one TB data clerk and one person for HIV
counselling and testing [HCT]). The aim was to develop the skills
of existing staff, provide support to manage the added HIV- and
ART- related activities, and absorb the increased workload.
The resulting services offered integrated TB and HIV case
management (including pre-ART care, ART initiation and follow-
up), management of sexually transmitted diseases, HCT, family
planning, and prevention. The integrated clinic enrolled patients
with HIV and/or TB, including patients who were HIV infected
but did not have TB, patients with TB who were HIV uninfected,
and TB/HIV co-infected patients. Once a week the mobile doctor
attended complicated medical cases and initiated ART in eligible
patients. TB diagnosis was based on sputum specimens, smear
microscopy or cultures, and/or the doctor’s clinical judgment [38].
HIV testing was offered to all TB patients. HIV-infected patients
were systematically screened for TB at every consultation using the
WHO symptom screen, enquiring on cough for more than 2
weeks, night sweats, loss of weight and fever. HIV co-infected
patients were assessed for eligibility for cotrimoxazole preventive
therapy, and CD4 cell count testing was performed. ART eligible
patients attended three pre-ART counselling sessions. TB clients
underwent directly observed treatment for the first 2 weeks. After
this initiation, stable and adherent co-infected patients collected
their antiretroviral drugs monthly and their TB drugs at weekly or
monthly intervals (depending on individual needs) - all from the
same pharmacy. Each patient had one medical file containing all
TB and HIV notes, counselling sheets, screening tools, and
prescription charts. Medical follow-up data were routinely entered
TB/HIV Integration Leads to Quicker ART Initiation
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into paper registers for ART and TB. To ensure complete TB
cohort reporting, information on HIV and ART status, CD4
count and cotrimoxazole prophylaxis were also recorded in the TB
register at the beginning of TB treatment.
Study Design, Inclusion and Exclusion Criteria, and
Definitions
This is a retrospective observational before-and-after study. To
select patients for inclusion in the analysis, we reviewed TB
registers and clinical files of TB/HIV co-infected patients aged
.16 years who were eligible for ART and registered for TB
treatment between June 1, 2008 and May 31, 2009 at the
intervention clinic. A TB case was defined as anyone registered for
TB treatment at Town 2 clinic, regardless of whether treatment
was initiated at the study clinic or elsewhere. An HIV case was
defined as anyone with an HIV positive test result recorded either
before or within a month of starting of TB treatment. If two or
more HIV test results were recorded for a given patient, the one
closest to the TB treatment initiation date was considered. Patients
on ART at the time of TB treatment initiation were excluded from
the analysis. Those who received at least one dose of ART after
starting TB treatment were classified as initiated on ART.
Eligibility for ART was defined as anyone with a CD4 cell count
at or below 250 cells/ml, measured 6 months before or after the
TB treatment start date. South African national guidelines during
this study’s period of observation recommended initiating ART in
patients with WHO stage IV and/or CD4,200 cells/ml.
However, we followed local clinical practice, which was to initiate
ART at CD4,250 cells/ml. The South African TB guidelines at
the time recommended initiation of ART after 2 months of TB
treatment for patients with CD4 counts 50–200 cells/mL and/or
WHO stage 4, and after 2 weeks for patients with CD4,50 cells/
mL. Patients with CD4.200 cells/mL were not eligible for ART
[38,39].
Data Management and Statistical Analysis
Data were recorded in an electronic database and checked for
errors and inconsistencies. TB and HIV information were
obtained from TB registers; identification information was
matched either with an electronic HIV patient database or with
paper-based ART registers from HIV referral clinics in Khayelit-
sha. Patient files were traced to obtain detailed HIV information
and to validate records from TB registers. Each patient was
followed until the date of an endpoint event, which was (1) ART
initiation; (2) death; (3) last visit before being lost to follow up
(LTFU), transferred out (TFO) or experiencing TB treatment
failure; or (4) end of the study observation period (275 days after
TB treatment start) for patients not initiated on ART. Patients
known to have initiated ART during TB treatment but without
recorded dates were assumed to have begun at the end of TB
treatment. Those with unknown ART status were censored at the
end of TB treatment.
We described and compared baseline characteristics of patients
before and after service integration using Chi square or Fisher’s
exact tests for categorical variables and Student’s t- or Wilcoxon
rank-sum test for continuous variables. Estimates of median time
Figure 1. Roles of health staff in Town 2 clinic after TB/HIV service integration. Model of care as it was implemented in Town 2 clinic in
December 2008.
doi:10.1371/journal.pone.0046988.g001
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to ART initiation were determined using Kaplan-Meier survival
analysis. We used log-rank tests and Cox proportional hazards
regression analysis to describe univariate associations between
baseline factors and time to ART initiation. Potential confounders
were determined a priori using directed acyclic graphs (DAGs,
described in Figure S1), and were included in a multivariate
proportional hazards Cox regression model. Variables were tested
for interactions, and Schoenfeld residuals were used to validate the
proportional hazard assumption. Collinearity was assessed by
calculating the variance inflation factors (VIF). All data were
analyzed using STATA version 11.0 (StataCorp, College Station,
Texas, USA).
Sensitivity Analysis
We also performed other sensitivity analyses (SA). Though not
identified in DAGs as potential confounders, we included the
variables TB classification and TB patient category (SA 1),
excluded all patients who initiated TB treatment in another facility
(SA 2), and categorized continuous variables (SA 5). Patients with
unknown exact ART initiation dates during TB treatment were
excluded (SA 3), or ART initiation was assumed to have occurred
in the middle of TB treatment (SA 4). Finally, in accordance with
national guidelines, only patients with CD4 cell counts equal to or
less than 200 cells/ml were considered eligible for ART (SA 6).
Ethics
The research protocol was approved by the Health Sciences
Faculty Research Ethics Committee of the University of Cape
Town (REC REF 222/2010) and the City of Cape Town Health
Directorate Research Committee. Individual patient consent was
waived by the Ethics Committee, consistent with the South
African Medical Research Council’s Guidelines on Ethics for
Medical Research and the Declaration of Helsinki, because this
was a retrospective analysis of routine clinical service records, no
additional data collection or procedures were undertaken from or
on patients, all patient information was entered into the database
using coded identification numbers, and no information that could
reveal patient identity was entered into the database.
Results
Study Subjects and Baseline Characteristics
We identified 552 TB patient records during the study period,
of which 343 did not meet the inclusion criteria (Figure 2). Of the
remaining 209 potential study participants, 21 (10.0%) were
excluded because eligibility could not be assessed. There were no
statistically significant differences in sex, age, TB patient category,
TB classification or TB initiation (in referral clinic) between
included and excluded participants (data not shown). In total, 343
TB patients (62.1%) were co-infected with HIV; 134 (39.1%) had
CD4 cell counts.250 cells/ml and/or were on ART at the start of
TB treatment.
The remaining 188 patients (90.0%) accrued 56 person-years of
observation, with a median follow-up duration of 102.5 days (IQR
49.5–188) and 57 days (IQR 32–163.5) for the periods before and
after service integration. Exact dates of ART initiation during TB
treatment and ART status at the end of TB treatment were
unknown for 15 and 16 patients respectively. The median age and
CD4 cell count were 35 years (IQR 29–40) and 87 cells/ml (IQR
37–136). Half the patients were male; 73.1% (n= 136) were new
TB cases; 38.8% (n= 73) commenced TB treatment in another
clinic; and 64.4% (n= 121) and 30.3% (n= 57) were diagnosed
with pulmonary or extra-pulmonary TB (Table 1). There were no
statistically significant differences between patients before and
after TB/HIV service integration regarding sex, age, CD4 cell
count, TB patient category and TB initiation (Table 1). Seventy
four (74.0%) pre-integration patients and 64 (72.7%) post-
integration patients initiated ART during the observation period,
and the remaining ones (death, LTFU, TFO, TB treatment
failure, reaching end of observation period) were censored
(Figure 2). Extra-pulmonary TB increased from 23.0% to
38.6% after integration, while pulmonary TB decreased from
70.0% to 58.0% (p= 0.051).
Outcomes
In total, 138 patients (73.4%) initiated ART. After full TB/HIV
integration, the estimated median time from TB treatment start to
ART initiation decreased from 147 days (95% CI 85–188) to 75
days (95% CI 52–119) (Figure 3). Service integration and lower
CD4 cell count were associated with shorter time to ART
initiation in univariate analysis (Table 2). After controlling for
gender, age, CD4 cell count and TB initiation, we found that
patients attending the integrated TB/HIV service were 1.60 (95%
CI 1.11–2.29) times more likely to start ART compared to patients
attending the service before integration. In all sensitivity analyses
our estimates continued to show a positive impact of the integrated
service, with adjusted HRs in the range from 1.56 to 1.80
(Table 3).
Discussion
To our knowledge, this is the first study to assess time until ART
initiation in patients before vs. after TB/HIV service integration.
It highlights that TB/HIV integration is feasible in the setting
described here and shows that positive outcomes for co-infected
patients can be realized immediately: estimated median time from
TB treatment start until ART initiation decreased from 147 to 75
days after integration. We also found that patients who received
care through this integrated model were 60% more likely to
initiate ART. These findings were robust to multiple sensitivity
analyses.
In the fully integrated TB/HIV integration model described
here, a single facility (primary health centre) and a single health
care provider delivered care for both diseases. In addition to its
apparent advantage in providing faster initiation of ART
treatment for TB patients, this model of care has several
advantages over more vertical, less integrated programs. An entire
intervention package was implemented consisting of initial
evaluation of clinical care and systems in the facility, followed by
training and regular hands on mentoring to enhance system
efficiency to cater for increasing patient load. As the number of
patients on ART increased, an extra nurse and a roving part time
doctor were added (after the period considered in this analysis). A
recent systematic review suggests integrated models may also
overcome challenges such as losing patients to follow-up during
the referral process between TB and HIV services, and burdening
patients with increased travel costs and more time spent in clinics
[21]. In our study the proportion lost to follow-up was higher after
integration, although this difference was not statistically significant.
A recent study in the same setting demonstrated that assessment at
an ART clinic during TB treatment reduced loss to follow-up by
80% [40]. Hermans et al. reported a decrease of TB treatment
default after integration of HIV and TB services in a large urban
HIV clinic in Uganda [41]. The ‘‘two diseases, one patient, one
service, one appointment, one health care worker’’ approach also
builds clinic staff’s expertise and experience in managing co-
infected patients and thus better addresses patients’ considerable
clinical challenges, including drug interactions and toxicity, IRIS,
TB/HIV Integration Leads to Quicker ART Initiation
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TB deterioration and optimal timing of ART initiation. In
addition, adherence and social support interventions within
integrated programs can mutually reinforce each other rather
than competing for scarce resources. Lastly, integration helps
improve efficiency of service delivery by avoiding duplication of
logistic and administrative services.
We identified several factors that contributed to success in fully
integrating our TB and HIV services: (1) getting buy-in from
management, clinicians and other service providers; (2) providing
training that improves competencies to treat both diseases; (3)
mentoring TB staff on ARV care in the initial stages of integration;
and (4) changing management processes to clarify defined areas of
accountability for health staff.
Potential obstacles at the clinic level must be addressed in
advance. These can include staff constraints, space, patient flow,
provision of drugs, and clinical challenges. For instance, clinicians’
fear that patients with severe TB infections will develop serious
ARV side effects, such as immune reconstitution inflammatory
syndrome (IRIS) and drug toxic events, may lead them to delay
ART initiation [28]. However, IRIS during early ART initiation is
clinically manageable [42]. A study from South Africa reported
that both IRIS and drug adverse events were rare in patients on an
efavirenz-based treatment regimen [31]. WHO recommends ART
initiation as soon as possible after TB treatment start and
regardless of the patient’s immunological status [43].
Concerns that integrated clinics increase the spread of TB in
immune compromised patients also need to be addressed. A study
from KwaZulu-Natal found that nearly 80% of deaths in an
integrated clinic were due to multi-drug and extensive drug
resistant TB (MDR and XDR) [31]; however, it remains unknown
whether transmission in those patients occurred at the facility level.
The authors stressed that HIV patients with unknown TB
infection pose the greatest risk of transmission in high HIV
prevalence settings, and that integration reduces this risk through
active case finding leading to earlier identification and treatment
of TB. HIV-infected patients in our study were screened for TB at
Figure 2. Flow chart of patients included in the study in Town 2 clinic from June 2008 to May 2009. Legend: TB, tuberculosis; ART,
antiretroviral treatment; TFO, transferred out; LTFU, lost to follow-up.
doi:10.1371/journal.pone.0046988.g002
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every visit. Moreover, diagnosed and undiagnosed HIV and TB
patients also come into close contact in non-integrated clinics and
in community settings (taxis, halls, homes and others), especially in
high prevalence settings [44]. Thus infection control is crucial in
TB and HIV high prevalence areas regardless of the level of health
care integration. Whilst implementation of infection control
measures is the responsibility of clinic staff, it requires a targeted
focus for measures to be consistently implemented. Increased focus
on infection control throughout the health sub-district of
Khayelitsha was made possible thanks to the addition of an
infection control officer.
Strengths and Limitations
Randomised controlled trials are the gold standard design for
evaluating complex interventions, but are not always possible
because of practical, ethical, financial or methodological difficul-
ties [45,46] and may not accurately reflect an intervention’s
feasibility or effectiveness in a real-world setting (i.e. have limited
applicability) [47]. To evaluate an intervention that had already
been implemented, we chose a before/after study design and used
several strategies to reduce the weaknesses of this design to limit
bias and confounding [46]. One strategy was to use a short (6
month) observation period before and after the intervention to
Table 1. Baseline characteristics of TB/HIV co-infected patients included in the study in Town 2 clinic from June 2008 to May 2009.
Service integration
All Before After p-value
Total enrolled 188 100 88
Sex; n (%) Female 95 (50.5) 50 (50.0) 45 (51.1) 0.876
Male 93 (49.5) 50 (50.0) 43 (48.9)
Age (years), median (IQR) 35 (29–40) 35.5 (28–41.5) 34 (30–40) 0.820
CD4 count; (cells/ml), median (IQR) 87 (37–163) 87.5 (50–169) 83.5 (31.5–157.5) 0.381
TB treatment category; n (%) New 136 (73.1) 72 (72.7) 64 (73.6) 0.898
Re-treatment 50 (26.9) 27 (27.3) 23 (26.4)
TB initiation*; n (%). In clinic 115 (61.2) 59 (59.0) 56 (63.6) 0.775
Outside clinic 1–14 days 41 (21.8) 22 (22.0) 19 (21.6)
15–60 days 25 (13.3) 14 (14.0) 11 (12.5)
$61 days 7 (3.7) 5 (5.0) 2 (2.3)
TB classification; n (%) Pulmonary 121 (64.4) 70 (70.0) 51 (58.0) 0.051
Extrapulmonary 57 (30.3) 23 (23.0) 34 (38.6)
Both 10 (5.3) 7 (7.0) 3 (3.4)
TB Rx, TB treatment; IQR, interquartile range. *In clinic: TB treatment initiated in study clinic; outside clinic: number of days of TB treatment received in referral clinic
before TB registration and treatment continuation in the study clinic.
doi:10.1371/journal.pone.0046988.t001
Figure 3. Kaplan-Meier curve for time from start of TB treatment to ART initiation for before and after service integration in Town 2
clinic from June 2008 to May 2009.
doi:10.1371/journal.pone.0046988.g003
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limit the influence of temporal trends over results and minimize
history effect bias [48]. Due to this short time span, our study was
completed when national [17] and WHO [16] treatment
guidelines were changed in 2010 to recommend starting ART at
an earlier time (between 2 and 8 weeks after start of TB treatment)
and at higher CD4 counts (,350 from ,200 cells/mL before). To
guard against chance findings we specified potential confounders a
priori based on directed acyclic graphs [49–51], and demonstrated
robustness to a range of sensitivity analyses. As in all observational
studies, unmeasured confounding cannot be ruled out completely.
Selection bias is another potential weakness of before/after
studies, since the before and after groups may differ. This study
excluded about 10% of patients from the analysis because their
eligibility could not be properly assessed. Most of this ambiguity
arose from difficulties tracing patient records in ART referral
clinics, since the previous vertical HIV and TB services each used
their own unique patient identification numbers. Reasons for non-
identification (and thus exclusion) included: (1) false identification
information provided by patient to conceal identity; (2) deaths and
LTFU occurring during the referral period; (3) patient not coming
to clinic for ART services during the observation period; (4)
patient accessing HIV care outside the health sub-district; or (5)
inaccurate patient record keeping. Exclusion was addressed by
comparing baseline characteristics of patients included and
excluded. No differences were detected between included and
excluded patients, nor between the before and after groups.
Most evaluation studies of TB/HIV integration to date have
assessed the effectiveness of service integration using intermediate
outcomes as metrics (e.g. percentage of TB patients with known
HIV status); few studies have examined actual health outcomes
and/or used a comparison group [21]. We used time to ART
initiation as a proxy indicator for mortality and improved health
outcomes. It is well documented that delayed treatment initiation
for patients with CD4 cell counts below 200 cells/ml is a strong
predictor of increased mortality [52,53]. Observational studies also
indicated that early ART initiation during TB treatment decreases
pre-ART mortality [9,10,13,42]. These findings were confirmed
by a randomized controlled trial from Cambodia [42] showing
that mortality of co-infected patients was reduced by 34% in the
early ART initiation arm at 2 weeks versus 8 weeks, as well as by
observational data [14].
Finally, this study is limited by the small sample size and the fact
that it was implemented in only one site in an urban South African
township. The findings need to be confirmed by larger studies in
different settings.
Conclusions
In this study TB/HIV integration resulted in immediate benefits
for patients. The study further demonstrates the feasibility of
integration in a peripheral primary care clinic using a nurse-led
model with limited support from medical doctors. The setting is
representative of many resource-constrained primary health care
settings facing dual HIV and TB epidemics. Our findings add to
the body of evidence supporting the rapid scale-up of service
integration in settings with a high TB/HIV co-infection burden.
Supporting Information
Figure S1 Directed Acyclic Graph. The following steps were
used to determine the set of variables to control for confounding:
Table 2. Cox proportional hazards models for the effect of TB/HIV integration and baseline covariates on time to ART.
Univariate analysis Multivariate analysis (n = 188)
cHR 95% CI p-value aHR 95% CI p-value
Service integration Before 1 1 0.011
After 1.63 1.13–2.33 0.008 1.60 1.11–2.29
Sex Female 1 0.282 1 0.238
Male 0.82 0.57–1.18 0.80 0.56–1.16
Age; per 10 years 1.01 0.82–1.26 0.897 0.98 0.77–1.24 0.840
CD4 count; per 50 cells/ml 0.81 0.71–0.92 0.002 0.81 0.71–0.92 0.002
TB Rx initiation*; per 14 days 0.91 0.81–1.03 0.131 0.91 0.80–1.03 0.123
cHR, crude Hazard Ratio; CI, confidence interval; aHR, adjusted Hazard Ratio;
*The number of days that TB treatment was received in referral clinics before TB registration and treatment continuation in the study clinic. After adjusting for gender,
age, CD4 count and previous TB initiation, patients were 60% more likely to initiate ART after service integration.
doi:10.1371/journal.pone.0046988.t002
Table 3. Sensitivity analyses and assumptions of different
models in multivariate Cox proportional hazards regression
analyses.
Adjusted
HR 95% CI p
Observations
(n)
Main analysis 1.60 1.11–2.29 0.011 188
SA 1 1.64 1.13–2.37 0.009 186
SA 2 1.80 1.12–2.88 0.014 115
SA 3 1.65 1.11–2.46 0.014 157
SA 4 1.59 1.10–2.30 0.013 186
SA 5 1.56 1.09–2.25 0.016 188
SA 6 1.67 1.13–2.43 0.010 163
Adjusted hazard ratios (HR) of ART initiation after integration compared to
before integration in alternative Cox proportional hazards models. The baseline
model is the one presented in table 2 and includes the following variables:
gender, age, CD4 count and previous TB initiation. SA, Sensitivity analysis; (n),
number; SA 1: inclusion of the variables TB classification (pulmonary TB; extra-
pulmonary TB; both pulmonary and extra-pulmonary TB) and TB patient
category (new TB case; re-treatment TB case) into the model; SA 2: exclusion of
patients transferred in from other TB services; SA 3: exclusion of patients with
unknown exact ART initiation date during TB treatment; SA 4: patients with
unknown exact ART initiation date during TB treatment assumed to have
initiated ART in the middle of TB treatment; SA 5: categorization of continues
variables (age, sex, TB Rx start outside of clinic); SA 6: only patients with CD4
cell counts #200 considered as according to national guidelines.
doi:10.1371/journal.pone.0046988.t003
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(1) First, we removed all variables which satisfied both being non-
ancestors of the intervention and being non-ancestors for the
outcome (none variables excluded). (2) Then lines emanating from
the intervention were eliminated (lines to Time to ART initiation,
Patient’s & health care provider’s attitude towards ART initiation, TB
classification) and every pair of variables with a common child or
descendant was connected by undirected arcs (Sex and Age, CD4
count at TB diagnosis and Patient’s & health care provider’s attitude towards
ART initiation, TB classification and Patient’s & health care provider’s
attitude towards ART initiation, TB classification and TB treatment
category, CD4 count at TB diagnosis and TB treatment category.) (3)
Then all arrowheads were removed from lines. (4) Finally,
variables were removed from the diagram (by deleting lines
touching these variables) until the intervention and outcome was
disassociated. Thus unblocked paths were closed and variables
included in the final model to control for confounding were
identified (sex, age, CD4 count, TB Rx initiation).
(PDF)
Table S1 Comparison of activities pre- and post-
integration.
(DOCX)
Poster S1 Tuberculosis Infection Control Policy Poster.
(PDF)
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